Dystrophic heart failure blocked by membrane sealant poloxamer.
about
Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophyHierarchical accumulation of RyR post-translational modifications drives disease progression in dystrophic cardiomyopathyLong-term blinded placebo-controlled study of SNT-MC17/idebenone in the dystrophin deficient mdx mouse: cardiac protection and improved exercise performanceSildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiencyAnnexin-A5 assembled into two-dimensional arrays promotes cell membrane repairCurrent understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophyThe membrane-active tri-block copolymer pluronic F-68 profoundly rescues rat hippocampal neurons from oxygen-glucose deprivation-induced death through early inhibition of apoptosisApoptosis repressor with a CARD domain (ARC) restrains Bax-mediated pathogenesis in dystrophic skeletal musclePrevalence and distribution of regional scar in dysfunctional myocardial segments in Duchenne muscular dystrophy.Dystrophin deficiency in Drosophila reduces lifespan and causes a dilated cardiomyopathy phenotype.Diastolic dysfunction and thin filament dysregulation resulting from excitation-contraction uncoupling in a mouse model of restrictive cardiomyopathy.Axial stretch of rat single ventricular cardiomyocytes causes an acute and transient increase in Ca2+ spark rateX-ROS signalling is enhanced and graded by cyclic cardiomyocyte stretch.Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophyStructural and functional recovery of electropermeabilized skeletal muscle in-vivo after treatment with surfactant poloxamer 188.Gene printer: laser-scanning targeted transfection of cultured cardiac neonatal rat cells.Functional substitution by TAT-utrophin in dystrophin-deficient mice.The dystrophin complex controls bk channel localization and muscle activity in Caenorhabditis elegans.Dystrophic Cardiomyopathy-Potential Role of Calcium in Pathogenesis, Treatment and Novel TherapiesChronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs.Differential effects of commercial-grade and purified poloxamer 188 on renal functionMembrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.Role of dystrophin in airway smooth muscle phenotype, contraction and lung function.Subcellular Ca2+ signaling in the heart: the role of ryanodine receptor sensitivity.Effects of PEO-PPO-PEO triblock copolymers on phospholipid membrane integrity under osmotic stressEx vivo stretch reveals altered mechanical properties of isolated dystrophin-deficient hearts.Mouse intact cardiac myocyte mechanics: cross-bridge and titin-based stress in unactivated cells.Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease.Lengthening-contractions in isolated myocardium impact force development and worsen cardiac contractile function in the mdx mouse model of muscular dystrophy.Beta-blockers, left and right ventricular function, and in-vivo calcium influx in muscular dystrophy cardiomyopathy.One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice.Dystrobrevin increases dystrophin's binding to the dystrophin-glycoprotein complex and provides protection during cardiac stressVBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.A high-throughput model of post-traumatic osteoarthritis using engineered cartilage tissue analogsEarly right ventricular fibrosis and reduction in biventricular cardiac reserve in the dystrophin-deficient mdx heart.Poloxamer [corrected] 188 has a deleterious effect on dystrophic skeletal muscle function.S100 and annexin proteins identify cell membrane damage as the Achilles heel of metastatic cancer cells.Sarcolemma instability during mechanical activity in Largemyd cardiac myocytes with loss of dystroglycan extracellular matrix receptor functionDistinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex.SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice
P2860
Q24295360-DB0E3E41-194C-4FB7-BB03-87E7A92D9644Q24306846-2083DE2E-C4E0-4804-BFC5-E6EE562C4405Q24655319-9BC088B0-D5A0-4F72-9406-90A88DD72E07Q24655371-A63169BD-34C0-4F50-B4BB-4D62A2180B7EQ27667441-66A7F4CD-44F2-434C-99EC-51E994ECFFCEQ28082625-E2DF0862-4D84-447F-B9C1-ADCCD70EBF4BQ28386144-697AF80B-E7FA-4252-BC5A-8F75873467F1Q28511114-AAFE1AEE-5901-4E1F-B3A7-8FBC1DF89A9CQ30432693-F6175252-A42B-44D0-AB2D-26EA1E298C50Q30493760-BD88F56D-BD04-4631-B82A-5693D87024CFQ30524974-E4492768-E4FF-4D89-92E6-9C3BC1A01BC3Q30529903-1D23ED4E-1954-4277-B54E-BE051D2F45E7Q30539103-6FC7A773-A04A-47DA-9664-C5C2535B71E2Q30545559-DFD6735B-B7CD-4C03-83C7-663B57F77305Q31106750-35129AA4-CE1B-4729-875D-B735194B0E3CQ33254358-D1E02DA5-3E54-48A0-BE1C-E2E7504AE153Q33455443-A24914C1-68F5-4F67-9CEA-F67FDA61CC33Q33519519-547D27BA-041A-4E49-BC96-C308FD95DAC8Q33608478-9FDA4799-26DE-4B10-B374-05D60EF053E8Q33755416-05339090-387D-4F41-B6FA-67F3E50484FFQ33804760-943E6CDA-FEDA-47CE-B4B4-A1341F15678DQ33901556-835A98FE-A595-4F19-9E26-DFDDB22216F5Q33939933-21CCE48B-FA29-490C-8D7C-BD9148C9D10DQ34028253-F944DC1D-D17B-4136-81CA-CE6AE198A022Q34087123-EDDEDC6C-6C8E-4C4C-94D1-1855C2016538Q34200139-30704D30-C21E-4CD3-9B6B-E848D9A65219Q34439598-3AAD1DC1-1B0A-4D5E-925D-6113C96B4408Q34508301-7EC20343-761E-4AB9-8DE4-633137156D21Q34598590-8903667B-36FF-4C37-9D4D-31DCDFB18B21Q34600310-BD77485A-34BB-4F3C-850B-8BBD7572614AQ34621772-834CA5CF-73B5-4EBF-A8E2-3EDF7545E02DQ34737660-243DE386-AFC5-4155-A4EB-9D408A63A359Q34981147-48BF4A85-52E4-4109-A73E-EBEB3FE558F4Q35037292-8B576CF0-9721-488D-B08D-F34BE731C6A4Q35086442-49093B54-11AA-454A-BFC2-5C9998E4E271Q35123905-1C5B320E-B8FE-45DC-9DD4-76445D688EC3Q35141257-47F45977-B3B8-4219-B2B4-F822075B37A7Q35155971-0C9199F1-CCA6-42F8-AD51-88C621059A36Q35169510-E86ADB9C-BC70-4B41-98A0-E8EA2BD6A61BQ35183186-E2929361-2438-4C30-993D-40FBCB150464
P2860
Dystrophic heart failure blocked by membrane sealant poloxamer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Dystrophic heart failure blocked by membrane sealant poloxamer.
@en
Dystrophic heart failure blocked by membrane sealant poloxamer.
@nl
type
label
Dystrophic heart failure blocked by membrane sealant poloxamer.
@en
Dystrophic heart failure blocked by membrane sealant poloxamer.
@nl
prefLabel
Dystrophic heart failure blocked by membrane sealant poloxamer.
@en
Dystrophic heart failure blocked by membrane sealant poloxamer.
@nl
P2093
P356
P1433
P1476
Dystrophic heart failure blocked by membrane sealant poloxamer.
@en
P2093
Daniel E Michele
DeWayne Townsend
Elizabeth G Favre
Joseph M Metzger
Sharlene M Day
Soichiro Yasuda
P2888
P304
P356
10.1038/NATURE03844
P407
P577
2005-07-17T00:00:00Z
P5875
P6179
1049868544